Gustavo Viani: Radiotherapy with durvalumab vs cetuximab advanced HNSCC
Gustavo Viani, Associate Professor in the Department of Medical Imaging, Hematology, and Oncology at Hospital das Clínicas, shared a post on LinkedIn about a recent paper by Loren Mell et al. published in The Lancet Oncology:
“Radiotherapy with durvalumab did not show higher outcomes over cetuximab for patients with advanced HNSCC unable to receive cisplatin‼️
Objective:
Investigated whether radiotherapy combined with concurrent and adjuvant durvalumab higher outcomes no to radiotherapy with cetuximab in patients with locoregionally advanced HNSCC who cannot receive cisplatin
Methods:
- NRG-HN004 was a multicentre, randomised, phase 2/3 trial
- Patients: 186 patients with stage III–IVB p16-negative HNSCC or high-risk p16-positive cases, ineligible for cisplatin due to factors like age, comorbidities, or renal/hearing issues.
- Treatment arms:
- Durvalumab Group: 1500 mg IV every 4 weeks with radiotherapy
- Cetuximab Group: 400 mg/m² IV weekly with radiotherapy
- First endpoint: Progression-free survival (PFS)
Results:
- At a median follow-up of 2.3 years:
- 2-year PFS: 50.6% for durvalumab vs. 63.7% for cetuximab (HR 1.33, p=0.89).
- Adverse events were comparable between groups:
- Common grade 3–4 events: dysphagia, lymphopenia, and oral mucositis.
- Treatment-related deaths: 3% (durvalumab) vs. 2% (cetuximab).”
Authors: Loren Mell, Pedro Torres-Saavedra, Stuart Wong, Sue Yom, Quynh-Thu Le et al.
More posts featuring Gustavo Viani.
Gustavo Viani, MD is an Associate Professor in the Department of Medical Imaging, Hematology, and Oncology at Hospital das Clínicas, Faculty of Medicine of Ribeirão Preto, University of São Paulo (FMRP-USP). Dr. Viani’s research focuses on radiation oncology, with expertise in brachytherapy, stereotactic radiosurgery, dose fractionation, radiation tolerance, and overall oncology practices.
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023